Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund holders during the fourth quarter of 2025. On February 20, the company ...

Exact Sciences Corporation EXAS is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

Due to their high-entropy nature, I’m not the biggest fan of specialized healthcare enterprises. With Exact Sciences (NASDAQ:EXAS) straddling the edge of biotech and medtech, EXAS stock represents a ...

Exact Sciences has published a new case study on its collaboration with Amalgam Rx and Privia Health, focused on colorectal ...

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue ...

Learn more about whether Exact Sciences Corporation or Avidity Biosciences, Inc. is a better investment based on AAII's A+ ...

Exact Sciences Corporation EXAS is well-poised to grow in the coming quarters, courtesy of its continuous investment in R&D efforts. In addition, EXAS’ commercial capabilities are driving stronger ...

Is Exact Sciences (NASDAQ: EXAS) about to go on a sustained run? The medical diagnostics specialist has lagged the market over the trailing-12-month period, but the stock is rebounding. In the past ...